(2/3)
"...challenges related to public confidence or awareness of our COVID-19 vaccine or Paxlovid, including challenges driven by misinformation, access, CONCERNS ABOUT CLINICAL DATA INTEGRITY and prescriber and pharmacy education;"

(all-caps are mine) pic.twitter.com/bAKH4iqiKs

— Kelly Brown (@rubiconcapital_) February 8, 2022